)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Wave Life Sciences
Wave Life Sciences (WVE) investor relations material
Wave Life Sciences Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary8 Jun, 2026
Strategic platform and pipeline evolution
Positioned at a strategic inflection point in 2026, advancing platform chemistry into meaningful therapies, notably WVE-007 for inhibin E, with phase II-A high BMI studies starting soon.
RNA editing platform is progressing, led by alpha-1 antitrypsin deficiency (AATD), with regulatory engagement this summer for potential accelerated approval and WVE-008 for PNPLA3 entering the clinic by year-end.
Platform leverages chemistry to unlock high-value genetic targets, enabling translation of clinical genetics into therapies for diseases like obesity and liver disorders.
Differentiation is driven by unique chemistry, enabling dual modalities such as silencing and upregulation within a single molecule, with further details to be shared at an upcoming R&D day.
WVE-007 (inhibin E) program insights
Inhibin E is a genetically validated target for obesity and cardiometabolic disease, with human data showing reduced visceral fat, improved lean mass, and lower lipid levels.
Preclinical and phase I data show single-dose reductions in body weight and fat, with muscle preservation and potential for combination and maintenance therapy with incretins.
Phase I healthy volunteer study demonstrated 15% visceral fat reduction, 5.4% subcutaneous fat reduction, and 3.3% waist circumference decrease.
Unique chemistry enables best-in-class siRNA performance, with improved potency, durability, and infrequent dosing (once or twice yearly).
Phase II-A will target high BMI patients with comorbidities, using MRI and DEXA endpoints, and explore dose optimization and broader cardiometabolic impacts.
Broader metabolic and combination opportunities
WVE-007 is positioned for use in obesity, diabetes, MASH, and other cardiometabolic diseases, with embedded biomarker analysis to unlock further indications.
Upcoming studies include combination with incretins and maintenance therapy to prevent weight regain after incretin cessation.
INHBE maintenance strategy after GLP-1 cessation
RNA editing advantages over AATD replacement
PNPLA3 correction versus silencing risks
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Wave Life Sciences
- Advancing a multi-modal RNA pipeline with pivotal data and regulatory milestones expected by 2026.WVE
Corporate presentation9 Jun 2026 - Diversified RNA pipeline advances toward major clinical milestones and strategic growth.WVECorporate presentation9 Jun 2026
- Q2 net loss widened to $32.9M as clinical pipeline advanced and cash runway remained strong.WVEQ2 20249 Jun 2026
- Q1 2025 net loss widened to $46.9M as clinical pipeline advanced; cash runway into 2027.WVEQ1 20259 Jun 2026
- INHBE, AATD, and PNPLA3 programs advance with focus on body composition and regulatory innovation.WVEJefferies Global Healthcare Conference 20263 Jun 2026
- WVE-006 achieved robust, durable efficacy and safety in AATD, supporting monthly dosing.WVEStudy update21 May 2026
- Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum.WVERBC Capital Markets Global Healthcare Conference 202620 May 2026
- Revenue surged and net loss narrowed in Q1 2026, with major clinical milestones on track.WVEQ1 20268 May 2026
- Shareholders will vote on redomiciling the parent company to Delaware, with board support.WVEProxy filing7 May 2026
Next Wave Life Sciences earnings date
Q2 202629 Jul, 2026
Wave Life Sciences
Next Wave Life Sciences earnings date
Q2 202629 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage